MedTrace Logo

Efficacy of Adding Topiramate to Current Treatment in Refractory Obsessive Compulsive Disorder (OCD)

NCT00182520 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2020-09-01

No results posted yet for this study

Summary

SRI's are considered first-line treatments for OCD, however many patients continue to have significant symptoms despite an adequate trial of an SRI. Neuroimaging studies have shown that the glutamate neurological system is involved in OCD. This study will test the safety and efficacy of topiramate, a drug, which targets glutamate, in the treatment of OCD, where the OCD has been un-responsive, or partially responsive to regular SRI treatment.

Conditions

  • Obsessive Compulsive Disorder

Interventions

DRUG

Topiramate

25 mg - 400 mg/day x 12 weeks

DRUG

placebo

25 - 400 mg/day x 12 weeks

Sponsors & Collaborators

  • Janssen-Ortho Inc., Canada

    collaborator INDUSTRY

  • Hamilton Health Sciences Corporation

    collaborator OTHER

  • McMaster University

    lead OTHER

Principal Investigators

  • Michael VanAmeringen, MD, FRCPC · McMaster University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-01-31
Primary Completion
2019-01-31
Completion
2019-01-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00182520 on ClinicalTrials.gov